期刊
GENE THERAPY
卷 12, 期 -, 页码 S28-S35出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.gt.3302613
关键词
retroviral gene transfer; replication-competent retrovirus; vector production
类别
资金
- NCRR NIH HHS [U42 RR11148] Funding Source: Medline
- NHLBI NIH HHS [P01 HL53586] Funding Source: Medline
- NIDDK NIH HHS [P50 DK49218] Funding Source: Medline
The National Gene Vector Laboratory (NGVL) is a US National Institutes of Health initiative charged with providing clinical grade vectors for gene therapy trials. The program was started in 1995 and Indiana University has served as the production site for retroviral vectors and is also accepting applications for production of lentiviral vectors. The facility is designed to produce vectors for Phase I and Phase II clinical trials with the specific mandate to facilitate investigator-initiated research for academic institutions. To date, the facility has generated over 30 Master Cell Banks for gene therapy investigators throughout the United States. This required the facility to develop a system that can adapt to the varied needs of investigators, most of whom request different vector backbones, packaging cell lines, final product volumes, and media. In this review, we will illustrate some of the experiences of the Indiana University NGVL during the generation of retroviral vectors using murine-based packaging cell lines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据